Vaccine for cervical cancer precursors holds promise

Article

If proven effective, the vaccine, called VGX-3100, would be the first non-ablative therapy for cervical precancer.

Results of a Phase IIb study suggest that a vaccine composed of synthetic plasmids that target HPV 16 and HPV 18 E6 and E7 proteins may have promise as a treatment of cervical intraepithelial neoplasia (CIN)2/3. If proven effective, the vaccine, called VGX-3100, would be the first non-ablative therapy for cervical precancer.

Published in The Lancet, the findings are from a randomized, double-blind, placebo-controlled trial conducted in 167 patients from 36 academic and private gynecology practices in 7 countries. Of the women, 125 received 6 mg VGX-3100 and 42 received 1 mL placebo, each given intramuscularly at 0, 4, and 12 weeks. Randomization was stratified by age (<25 vs ≥25 years) and CIN2 versus CIN3 by computer-generated allocation sequence (block size 4). Regression to CIN1 or normal pathology 36 weeks after the first dose was the primary endpoint.

Histopathological regression was seen in 53 (49.5%) of the patients who received VGX-3100 versus 11 (30.6%) of the patients who received placebo (95% confidence interval [CI] 1.4-36.6; P=0.034). In the modified intent-to-treat analysis, 55 (48.2%) of 114 vaccine recipients and 12 (30%) of 40 placebo recipients had histopathological regression (percentage point difference 18.2 [95% CI 1.3-34.4; P=0.034]).

Most patients had injection-site reactions but only erythema was significantly more common in the group that received VGX-3100 than in those who received placebo (98/125, 78.4% vs. 24/42, 57.1%; percentage point difference 21.3 [95% CI 5.3-37.8; P=0.007]). 

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Susan Khalil, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Megan Wasson, DO, FACOG
Wasson and Colak
Non-hormonal treatments offer relief for genitourinary syndrome of menopause | Image Credit: providers.uthscsa.edu.
Chemen M. Neal, MD, discusses weekly secnidazole for bacterial vaginosis treatment | Image Credit: medicine.iu.edu
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
Ipek Ensari, PhD, highlights improved mental health in chronic pelvic pain from physical activity | Image Credit: scholars.mssm.edu
Evaluating a miniature robotic device for hysterectomy | Image Credit: linkedin.com.
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.